On February 14, 2018, the Food and Drug Administration approved apalutamide for patients with non-metastatic castration-resistant prostate cancer.
Apalutamide is used in conjunction with castration, either via bilateral orchiectomy or gonadotropin-releasing hormone analogue (GnRH analogue) therapy, as a method of androgen deprivation therapy in the treatment of NM-CRPC. It is also a promising potential treatment for metastatic castration-resistant prostate cancer (mCRPC), which the NSAA enzalutamide and the androgen synthesis inhibitor abiraterone acetate are used to treat. Apalutamide is provided in the form of 60 mg oral tablets. It is taken at a dosage of 240 mg once per day (four tablets) when used in the treatment of NM-CRPC.
Source Content : wikipedia
Head Office of Indian Pharma Network (IPN) is in New Delhi, INDIA.
For Indian Patients Apalutamide brands can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India.
For overseas patient Apalutamide brands in India can be also made available to overseas patients, doctors and hospitals. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
FDA Approves Apalutamide for Nonmetastatic Prostate Cancer.